Expanding Market Presence Thirona's LungQ® platform is already installed in over 1,200 hospitals worldwide, indicating a strong foothold and potential for further expansion into new healthcare markets and partnerships with hospital networks seeking advanced pulmonary imaging solutions.

Innovative Product Launches The recent launch of LungQ AVX and ongoing development of AI algorithms for COVID-19 and vascular lung disease analysis highlight the company's commitment to innovation, creating opportunities to upsell or cross-sell these advanced features to current clients and attract new customers needing cutting-edge diagnostic tools.

Strong Research Validation Validated by over 200 peer-reviewed publications, Thirona’s solutions demonstrate clinical credibility and reliability, which can be leveraged to establish trust with healthcare providers, research institutions, and pharmaceutical companies interested in AI-driven diagnostic advancements.

Funding and Growth Trajectory With recent investments totaling over $8 million and support from the European Innovation Council, Thirona has shown robust financial backing, positioning it as a reliable partner for customers looking for innovative, well-funded health tech solutions seeking to enhance pulmonary diagnostics.

Strategic Collaborations Thirona's collaborations with research institutes, academic hospitals, and pharmaceutical innovators present opportunities for joint ventures, clinical trials, and development partnerships, opening avenues for sales through co-created solutions and expanded product adoption within the healthcare ecosystem.